Genentech: Tecentriq Misses Endpoint in Muscle-Invasive Urothelial Cancer

Date : 01/24/2020 @ 12:52PM
Source : Dow Jones News
Stock : Roche Holdings Ltd AG (QX) (RHHBY)
Quote : 39.89  -0.895 (-2.19%) @ 9:59PM
After Hours
Last Trade
Last $ 39.89 ◊ 0.00 (0.00%)

Genentech: Tecentriq Misses Endpoint in Muscle-Invasive Urothelial Cancer

Historical Stock Chart

2 Months : From Dec 2019 to Feb 2020

Click Here for more Roche (QX) Charts.

By Colin Kellaher


Roche Holdings AG's (ROG.EB) Genentech unit on Friday said a Phase 3 study of Tecentriq as an adjuvant monotherapy treatment missed its primary endpoint of disease-free survival in people with muscle-invasive urothelial cancer.

The company said safety for Tecentriq appeared consistent with the known safety profile of the immunotherapy drug, with no new safety signals identified.

"Reducing the risk that muscle-invasive urothelial cancer will recur after surgery is very difficult, and we are disappointed that we were not able to significantly prolong disease-free survival," Genentech said.

Genentech is conducting an extensive development program for Tecentriq, including ongoing and planned Phase 3 studies across bladder, genitourinary, skin, breast, gastrointestinal, gynecological and head and neck cancers.


Write to Colin Kellaher at


(END) Dow Jones Newswires

January 24, 2020 07:37 ET (12:37 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Latest RHHBY Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.